Phase 1 Oesophageal Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You are generally able to carry out some or all of your usual daily activities (your doctor will have rated your physical fitness on a standard scale as 0, 1, or 2)
- For the first part of the trial (Part A): You have been diagnosed with an advanced or spread cancer that cannot be removed by surgery, including certain types of colorectal cancer, lung cancer, breast cancer, stomach or esophageal cancer, or possibly other cancer types if approved by the trial team
- For the second part of the trial (Part B): You have been diagnosed with advanced colorectal cancer, advanced lung cancer, or another specific cancer type depending on which group (cohort) you are being considered for
- Your cancer is not considered curable and you have already tried standard treatments, could not tolerate them, or they are not suitable for you — with no other standard options remaining
- For colorectal cancer (Part B): You have already been treated with specific standard chemotherapy drugs and other targeted treatments, or they were not suitable for you
- For lung cancer (Part B): You have already been treated with standard platinum-based chemotherapy and an immunotherapy drug, or they were not suitable for you
- Your cancer can be measured on scans according to standard medical guidelines
Who may not be able to join:
- You have previously received a specific type of cancer drug (called an antibody-drug conjugate) that targets an enzyme called topoisomerase-1 — though people with lung cancer or breast cancer may have had up to one of these treatments
- You have had a serious allergic reaction (anaphylaxis) to certain chemotherapy drugs such as irinotecan, or to the type of drug being studied
- Your expected life expectancy is less than 12 weeks (confirm with trial site)
- You have previously had a solid organ transplant (such as a kidney, liver, or heart transplant)
- You have a build-up of fluid in your abdomen or around your lungs that is causing symptoms
- You have active cancer that has spread to your brain or the lining around your brain or spinal cord
- You have a history of another separate cancer diagnosis, unless you received treatment that may have cured it, you have had no signs of it returning for at least 2 years, and the trial team approves your participation
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: 425.939.7410
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Evaluate the safety and tolerability of IM-1617 in participants with unresectable locally advanced or metastatic solid tumors by incidence of adverse events (AEs) and serious adverse events (SAEs); Evaluate the safety and tolerability of IM-1617 in participants with unresectable locally advanced or metastatic solid tumors by incidence of AEs of interest (AEIs); Evaluate the safety and tolerability of IM-1617 in participants with unresectable locally advanced or metastatic solid tumors by incidence of AEs leading to discontinuation; Evaluate the safety and tolerability of IM-1617 in participant...
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.